…from regorafenib than do those with KIT/PDGFRA wild-type non-SDH-deficient tumors . There are no comparative trials of any other tyrosine kinase inhibitors (TKIs) in imatinib, sunitinib, and regorafenib-refractory …
… and non-cardiovascular toxicities. Most of the cardiovascular toxicities appear to be related to the effects of these agents on non-tumor vasculature. Some of the toxicities of the tyrosine kinase inhibitors …
… an N-terminal glycine residue . The ABL1 proteins are similar to the Src family of non-receptor protein-tyrosine kinases, and can phosphorylate cellular proteins on tyrosine residues. However, c-ABL1 has …
… molecule inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase. They are primarily used in the treatment of advanced non-small cell lung cancer (NSCLC). Approximately 1 percent of patients …
… most forms of treatment. Responses are short-lived, although responding patients survive longer than non-responders . There is a significant relapse rate in patients in blast crisis or accelerated phase even … which is a constitutively active tyrosine kinase. This deregulated tyrosine kinase is implicated in the development of CML…